Beijing Hammer Biotechnology

Hammer Biopharm is a clinical-stage biotechnology company headquartered in Beijing, China, specializing in the development of next-generation antibody-drug conjugates (ADCs). The company utilizes its proprietary Hammer-Link platform to create site-specific, stable, and homogeneous ADC candidates designed to improve therapeutic index and safety profiles. Their pipeline primarily targets various solid tumors with high unmet medical needs, including breast and gastric cancers. Hammer Biopharm aims to overcome the limitations of traditional conjugation methods through innovative linker-payload technologies. The company's lead candidate, HM-001, is currently undergoing clinical evaluation in patients with HER2-expressing malignancies. Backed by prominent venture capital firms, the company continues to expand its portfolio of precision oncology therapeutics.